Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
about
Treatment options in recurrent ovarian cancer: latest evidence and clinical potential.Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data.Optimal chemotherapy treatment for women with recurrent ovarian cancerProgression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles.How should we manage patients with "platinum-sensitive" recurrent ovarian cancer?Management of recurrent epithelial ovarian carcinoma.Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.Cost-utility analysis for platinum-sensitive recurrent ovarian cancer therapy in South Korea: results of the polyethylene glycolated liposomal doxorubicin/carboplatin sequencing modelRestoring platinum sensitivity in recurrent ovarian cancer by extending the platinum-free interval: Myth or reality?Biological Pathways Involved in Tumor Angiogenesis and Bevacizumab Based Anti-Angiogenic Therapy with Special References to Ovarian Cancer.Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial.Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.Advances in targeting the folate receptor in the treatment/imaging of cancers.
P2860
Q27692699-2BE31C38-36F8-4777-81CC-3209EFFF3FD5Q30689000-4B413042-1FB0-4A7D-9111-C1F6404538E1Q33302771-4AFBC796-19E1-4731-ACCB-8429760E4591Q34185403-C4A7B3D3-9306-49F3-8D88-150F67927AD1Q35968737-12CBADD6-DEDC-4A1D-9B6D-2895980C85A5Q36200382-97CFA454-FEE8-4B7A-80D4-DC001A886A59Q36648394-4E16D444-F272-4B95-AEFA-F4178DF5C002Q36996565-D687D3F3-D147-4619-9C6A-10439288049AQ38693066-C0A2104F-4F50-46A6-8961-12A85EFA5942Q41660578-6546A26B-DDF7-4149-9FED-2D7B62B00C5EQ48489815-AB4B703C-69E7-4782-9555-A7821F0C946DQ54524518-29555DA9-11DF-43B2-ABAD-FE9AD3564A7DQ55315165-28E276E5-EA0B-4601-88EE-4FD0C29A40BA
P2860
Carboplatin alone vs carboplatin plus epidoxorubicin as second-line therapy for cisplatin- or carboplatin-sensitive ovarian cancer.
description
2001 nî lūn-bûn
@nan
2001 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@ast
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@en
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@nl
type
label
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@ast
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@en
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@nl
prefLabel
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@ast
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@en
Carboplatin alone vs carboplat ...... atin-sensitive ovarian cancer.
@nl
P2093
P50
P356
P1433
P1476
Carboplatin alone vs carboplat ...... latin-sensitive ovarian cancer
@en
P2093
Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group
G Giardina
G Scarfone
M Melpignano
P356
10.1006/GYNO.2001.6151
P407
P577
2001-04-01T00:00:00Z